Summary
4.24
-0.12
(-2.64%)
04/14/2026
Perspective Therapeutics, Inc. (CATX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -2.64 | -0.46 | -13.00 | 73.31 | -9.94 | 112.20 | -58.17 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 4.24 | |
| Open | 4.39 | |
| High | 4.41 | |
| Low | 4.20 | |
| Volume | 752,005 | |
| Change | -0.12 | |
| Change % | -2.64 | |
| Avg Volume (20 Days) | 1,459,881 | |
| Volume/Avg Volume (20 Days) Ratio | 0.52 | |
| 52 Week Range | 1.75 - 6.16 | |
| Price vs 52 Week High | -31.25% | |
| Price vs 52 Week Low | 142.00% | |
| Range | -1.14 | |
| Gap Up/Down | -0.11 | |
Profitibility | ||
| Market Capitalization (Mln) | 163 | |
| Revenue per share | 0.0114 | |
| Net Income per share | -1.3971 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -3.1137 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/02 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming Investor Conferences
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership...
Perspective Therapeutics to Participate in Upcoming Investor Conferences
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership...
03/17 16:45 EST - globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's...
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's...
03/16 16:07 EST - globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a...
02/17 11:17 EST - prnewswire.com
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
02/17 07:00 EST - globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025...
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025...
02/07 01:08 EST - defenseworld.net
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast
Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk,...
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast
Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk,...
02/02 08:35 EST - globenewswire.com
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of...
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of...
02/02 02:00 EST - defenseworld.net
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership,...
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership,...
01/30 15:37 EST - seekingalpha.com
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. CATX's VMT-a-NET achieved 76% progression-free and alive status in SSTR2 NET patients, with pivotal mid-2026 data readouts expected to drive...
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. CATX's VMT-a-NET achieved 76% progression-free and alive status in SSTR2 NET patients, with pivotal mid-2026 data readouts expected to drive...
01/27 03:30 EST - defenseworld.net
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price traded down 4.4% during trading on Monday. The stock traded as low as $2.58 and last traded at $2.59. 732,483 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,137,457...
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price traded down 4.4% during trading on Monday. The stock traded as low as $2.58 and last traded at $2.59. 732,483 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,137,457...
01/14 21:46 EST - seekingalpha.com
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01/09 07:00 EST - globenewswire.com
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced...
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced...
01/04 01:55 EST - defenseworld.net
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and four have...
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and four have...
12/18 07:00 EST - globenewswire.com
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer,...
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer,...
12/14 01:59 EST - defenseworld.net
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst...
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst...
12/10 01:46 EST - defenseworld.net
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have...
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have...
11/20 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming December Conferences
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its...
Perspective Therapeutics to Participate in Upcoming December Conferences
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its...
11/11 23:11 EST - seekingalpha.com
Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript
Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of Investor Relations Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research...
Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript
Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of Investor Relations Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research...
11/10 16:05 EST - globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
SEATTLE, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today provided...
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
SEATTLE, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today provided...
10/31 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming November Conferences
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team...
Perspective Therapeutics to Participate in Upcoming November Conferences
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team...
Market News
×
Loading news…